Multimodal treatment of metastatic thymic carcinoma including high-dose chemotherapy with autologous stem cell transplantation: Report of a case with more than 4-year disease-free survival

David B. Geffen, Daniel Benharroch, Alon Yellin, Samuel Ariad, Reuven Or, Yoram Cohen

Research output: Contribution to journalArticlepeer-review

Abstract

Thymic carcinoma is a rare epithelial malignancy differentiated from thymoma by the presence of cytologically malignant cells. There are few reports of the treatment of locally advanced or metastatic thymic carcinoma. We describe a patient who sought treatment for thymic carcinoma metastatic to pleura, pericardium, retroperitoneum, and neck nodes. He was treated with neoadjuvant etoposide, ifosfamide, and cisplatin, and underwent resection. We then administered high-dose chemotherapy with autologous stem cell support, followed by radiation therapy. The patient remains in complete remission more than 4 years after diagnosis. To our knowledge, this is the first report of metastatic thymic carcinoma treated with neoadjuvant therapy and postoperative high-dose chemotherapy. Metastatic thymic carcinoma may be curable by aggressive combined therapies.

Original languageEnglish
Pages (from-to)566-569
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume24
Issue number6
DOIs
StatePublished - 2001

Keywords

  • High-dose chemotherapy
  • Neoadjuvant
  • Radiation therapy
  • Thymic carcinoma

Fingerprint

Dive into the research topics of 'Multimodal treatment of metastatic thymic carcinoma including high-dose chemotherapy with autologous stem cell transplantation: Report of a case with more than 4-year disease-free survival'. Together they form a unique fingerprint.

Cite this